AnaptysBio Inc (ANAB)

NASDAQ
31.27
+0.20(+0.64%)
After Hours
31.27
0.00(0.00%)
- Real-time Data
  • Volume:
    70,968
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    30.51 - 31.46

ANAB Overview

Prev. Close
31.07
Day's Range
30.51-31.46
Revenue
122.17M
Open
31.33
52 wk Range
17.72-37.89
EPS
0.31
Volume
70,968
Market Cap
860.17M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
172,605
P/E Ratio
101.61
Beta
0.14
1-Year Change
24.14%
Shares Outstanding
27,507,922
Next Earnings Date
Mar 07, 2022
What is your sentiment on AnaptysBio Inc?
or
Market is currently closed. Voting is open during market hours.

AnaptysBio Inc Company Profile

Employees
94

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company’s products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyStrong BuyBuy
Technical IndicatorsStrong BuyStrong BuyBuySellStrong Buy
SummaryStrong BuyStrong BuyBuyNeutralStrong Buy
  • HC Wainwright dropped their price objective on shares of Abeona Therapeutics from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, November 25th.
    0
    • Hi, I’m the second! Thinking to enter in this paper carefully.
      1
      • MY sweet Elena please do not do this . where are you from ? I am from Greece . You ? if you want to enter go to Vonage VG.
        0
      • you had right but now is late try to Vonage VG you will remember me if you will earn money come to Greece to visit me i am a Stock Consultant . Lefteris from Greece.
        0
    • I'm the first to comment! Lucky me!
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.